Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 28 July 2023, 06:00 HKT/SGT
Share:
    

Source: Peptomyc SL
Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients
OMO-103 in Phase 1b clinical trial

BARCELONA, July 28, 2023 - (ACN Newswire) - Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has received full study approval for its new Phase 1b clinical trial, which will evaluate the combination of the first-in-class MYC inhibitor, OMO103, together with the standard of care (SoC) regimen Gemcitabine and Nab-Paclitaxel in metastatic Pancreatic Ductal Adenocarcinoma (PDAC) patients in first line. PDAC is the most common form of pancreatic cancer. Currently, it is the fourth highest cause of cancer mortality worldwide and its incidence is rising steeply. Current therapies offer limited chance of a lasting cure and the five-year survival rate is one of the lowest among the most commonly occurring cancers.

MYC is an oncoprotein deregulated in most -if not all- types of cancers. It is activated in many PDAC cases, where it contributes to aggressiveness of the disease and resistance to treatments. The company recently completed a FIH Phase 1 study of OMO103 in all-comers solid tumor patients, demonstrating excellent safety and promising anti-tumor activity.

Manuela Niewel, MD, PhD, Chief Medical Officer of the company, leading Peptomyc's clinical development, regulatory and medical affairs activities, says: "I am excited to be able to start our new Phase 1b study in PDAC patients. With OMO-103, we hope to address this devastating disease and one of the highest unmet medical needs in the oncology field".

This Phase 1b combination study will be conducted in four sites in Spain. The lead PI will be Dr. Teresa Macarulla at the Vall d'Hebron Institute of Oncology in Barcelona, and she will collaborate with Dr. Andres Munoz at the Hospital Gregorio Maranon in Madrid, Dr. Mariona Calvo at the ICO-Hospitalet in Barcelona, and Dr. Roberto Pazo at the Hospital Miguel Servet in Zaragoza. The study is planned to start in Q3/2023.

About Peptomyc

Peptomyc (www.peptomyc.com) is a spin-off from VHIO - the Vall d'Hebron Institute of Oncology - and ICREA - the Catalan Institute of Research and Advanced Studies - founded in December 2014 in Barcelona, Spain. The company is focused on the development of innovative cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment and based on Dr. Soucek's scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years. It is the first company to have successfully completed a Phase I clinical trial with a direct MYC inhibitor.

Contact Information
Laura Soucek
CEO
lsoucek@peptomyc.com
+34695207869


Topic: Press release summary
Source: Peptomyc SL

Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Hong Kong International Jewellery Show opens today showcasing global innovative designs  
Mar 6, 2025 13:20 HKT/SGT
NEC improves the energy efficiency and floor space density of 5G Mobile Core systems  
Thursday, March 6, 2025 12:20:00 PM
Exceptional Presence of 24 Hong Kong Innovators Mesmerised Mobile World Congress Audience  
Mar 6, 2025 10:41 HKT/SGT
Singapore to Host the 24th Cyber Security Summit: Addressing Emerging Threats and AI-Driven Security  
Mar 6, 2025 10:16 HKT/SGT
Doubleview Gold Corp Announces Collaboration with Her Excellency Sheikha Sara Nasser Al-Thani CEO of Qmission W.L.L. Qatar  
Mar 6, 2025 09:09 HKT/SGT
Register Now: analytica Vietnam's Largest Edition & Must-See Innovations!  
Mar 6, 2025 07:32 HKT/SGT
General Atomics Introduces Quadratix Software Enterprise  
Mar 5, 2025 22:42 HKT/SGT
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open  
Mar 5, 2025 21:51 HKT/SGT
Giftify, Inc. Launches Sports Ticket & Merchandise Savings Platform as Fan Expenses Surge  
Mar 5, 2025 21:30 HKT/SGT
Historic Global Anti-Scam Summit Convenes in London to Combat Escalating Online Fraud  
Mar 5, 2025 19:07 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: